10-Q: Baxter Reports Q3 Loss Amid Novum LVP Recall & Tax Charges

Baxter International Inc. reported a net loss for the third quarter of 2025, impacted by significant special items including tax reserves and costs related to the Novum LVP recall, despite overall sales growth.

Summary

• Net sales for the three months ended September 30, 2025, increased 5% to $2.835 billion, with operational sales growth of 2% compared to the prior year.
• Net sales for the nine months ended September 30, 2025, increased 5% to $8.270 billion, with operational sales growth of 2% compared to the prior year.
• The company reported a net loss attributable to Baxter stockholders of $(46) million, or $(0.09) per diluted share, for the third quarter of 2025, compared to net income of $140 million, or $0.27 per diluted share, in the prior year period.
• For the nine months ended September 30, 2025, net income attributable to Baxter stockholders was $171 million, or $0.33 per diluted share, compared to a net loss of $(137) million, or $(0.27) per diluted share, in the prior year period.
• Special items adversely impacted net income by $401 million ($0.78 per diluted share) in Q3 2025 and $780 million ($1.52 per diluted share) for the nine months ended September 30, 2025.
• Gross margin decreased to 33.5% in Q3 2025 from 38.3% in Q3 2024, and to 33.9% for the nine months ended September 30, 2025, from 38.4% in the prior year period, primarily due to the Kidney Care MSA impact, product mix, and unfavorable manufacturing variances.
• The sale of the Kidney Care business was completed on January 31, 2025, for $3.80 billion in cash, yielding approximately $3.3 billion in net after-tax proceeds.
• A pre-tax gain on the sale of $191 million ($111 million net of tax) was recognized, though reduced by $55 million in Q3 2025 due to final working capital adjustments.
• The company repaid $3.81 billion of shortand long-term indebtedness in the first nine months of 2025, primarily using proceeds from the Kidney Care sale.
• Quarterly cash dividends declared per share were $0.17 for Q3 2025, down from $0.29 in Q3 2024.
• The company recorded $300 million in reserves for uncertain tax positions related to IRS transfer pricing matters for tax years 2019 through 2025.
• Andrew Hider was appointed Chief Executive Officer in Q3 2025, leading to a change in the Chief Operating Decision Maker.

Sentiment

Score: 3

Explanation: The company reported a net loss for the quarter, a significant decline in gross margin, and faced substantial special charges including tax reserves and product recall costs. Operational challenges from the Novum LVP recall and reduced IV solution demand are expected to persist. While debt reduction from the Kidney Care sale is positive, the negative credit rating outlook and reduced dividends reflect underlying financial pressures and uncertainty.

Positives

• Overall net sales increased by 5% for both the three and nine months ended September 30, 2025.
• Advanced Surgery segment net sales increased 13% in Q3 2025 and 7% for the nine months, driven by increased sales volume globally.
• Care & Connectivity Solutions net sales increased 4% in Q3 2025 and 5% for the nine months, due to increased capital spending by U.S. customers and higher installations of care communications products.
• Drug Compounding net sales increased 12% in Q3 2025 and 6% for the nine months, driven by improved product mix and increased international demand.
• The sale of the Kidney Care business generated approximately $3.3 billion in net after-tax cash proceeds, which were used to repay $3.81 billion in debt.
• The Claris Injectables facility received a Voluntary Action Indicated (VAI) classification from the FDA on October 31, 2025, indicating acceptable compliance and expected closure of the 2023 Warning Letter.

Negatives

• Reported a net loss attributable to Baxter stockholders of $(46) million in Q3 2025, compared to net income of $140 million in Q3 2024.
• Income (loss) from continuing operations was $(51) million in Q3 2025, down from $61 million in Q3 2024.
• Gross margin ratio decreased significantly to 33.5% in Q3 2025 from 38.3% in Q3 2024, and to 33.9% for the nine months from 38.4% in the prior year.
• Infusion Therapies & Technologies net sales decreased 4% in Q3 2025 and 1% for the nine months, primarily due to lower Novum LVP pump sales and reduced U.S. demand for IV solutions.
• The company recorded $300 million in reserves for uncertain tax positions related to IRS transfer pricing matters, contributing to a high effective tax rate of 142% in Q3 2025.
• Moody's revised the senior debt credit rating outlook from stable to negative in Q3 2025 and placed senior secured, long-term debt, and commercial paper ratings on review for downgrade in November 2025.
• Quarterly cash dividends were reduced from $0.29 per share in Q3 2024 to $0.17 per share in Q3 2025.
• Operating cash flows from continuing operations were unfavorably impacted by increased inventory levels in the current year period.

Risks

• The Novum LVP recall and related temporary distribution/installation hold are expected to continue beyond 2025, with no additional sales anticipated during this period, and future returns or exchanges could have a material financial impact.
• Reduced demand in the IV solutions business due to customer fluid conservation practices, initiated after Hurricane Helene, is expected to continue beyond 2025.
• Ongoing IRS examination for transfer pricing matters (2019-2020 tax years) could result in material additional taxes, penalties, and interest beyond the $300 million already reserved.
• Potential for future goodwill impairment related to the Front Line Care reporting unit if the business outlook significantly changes.
• Exposure to product liability, patent, commercial, employment, and other legal matters, with outcomes inherently uncertain and potentially leading to material judgments or settlements.
• Risk of future administrative and legal actions from governmental and regulatory bodies, potentially leading to product recalls, injunctions, restrictions on operations, and monetary sanctions.
• Supply chain challenges, including impacts from weather events, macroeconomic/geopolitical events, and tariffs, which have negatively affected results and are expected to continue.
• Inability to pass on inflationary and other cost increases (e.g., shipping, labor, tariffs) to customers due to long-term contracts, potentially impacting profitability.
• Adverse changes in foreign currency exchange rates could increase raw material sourcing costs.
• Continued global macroeconomic uncertainty, including trade policies, tariffs, and geopolitical events, could lead to market volatility, weakened economic conditions, and decreased hospital capital spending.
• Potential for further downgrades to credit ratings or ratings outlooks, impacting funding costs and liquidity.
• Breaches and breakdowns affecting information technology systems or protected information, including cyber-attacks, data leakage, or unauthorized access.

Future Outlook

The company expects the temporary distribution and installation hold for the Novum LVP to continue beyond 2025, with no additional sales anticipated during this period. Reduced demand in the IV solutions business due to fluid conservation practices is also expected to continue beyond 2025, though the impact is projected to lessen over time. Additional pre-tax costs of approximately $1 million are expected for ongoing business optimization programs, with further restructuring charges possible as more cost savings opportunities are identified. The impact of the OBBBA and Pillar Two tax legislation on income tax expense for the year ending December 31, 2025, is not expected to be material. The company continues to monitor regulatory guidance and interpretations.

Management Comments

• We have incurred and expect to incur additional dis-synergies following our sale of our Kidney Care business due to the reduced size of our company and, as a result, we have begun to undertake certain restructuring actions (and intend to undertake additional actions) to help ensure our cost structuring is appropriate to support our remaining business.
• While the timing of this continued ship and installation hold remains uncertain, we currently expect it to be in place beyond 2025. Additionally, while we expect no additional sales of Novum LVP while these holds are in effect, our Spectrum IQ large volume pump is generally available as an alternative option for customers with Novum LVPs.
• While returns and exchanges of Novum LVP made to date are not material for our financial results, future returns or exchanges (including related costs) could have a material impact on our results in the future.
• We expect some hospital customers to continue a level of conservation through the remainder of 2025 and potentially beyond with the impact expected to lessen over time.
• While we believe that our transfer pricing positions are well documented, properly supported, and adequate amounts have been reserved to account for any adjustments that may ultimately result from this examination, the ultimate outcome of this matter is uncertain (upon the receipt of a NOPA or otherwise).
• If the IRS were to assert we owe additional taxes and prevails in this assertion, such outcome could have a material impact on our financial position, results of operations, and cash flows.
• There is a reasonable possibility within the next twelve months, we may reach a conclusion that an increase to the valuation allowance is needed on U.S. deferred tax assets. Our current valuation allowance is based on our historical and estimated future earnings. The timing and amount of any potential change in the valuation allowance could vary based on our future earnings (which may vary from current estimates).
• We currently expect that the impact of the OBBBA legislation on our income tax expense for the year ending December 31, 2025 will not be material. We will continue to monitor regulatory guidance and interpretations as they are issued.
• We currently expect that the impact of the Pillar Two legislation on our income tax expense for the year ending December 31, 2025 is not expected to be material. We will continue to evaluate the impact of legislative changes as additional guidance becomes available.

Industry Context

The healthcare industry continues to face challenges from global macroeconomic conditions, including inflation, supply chain disruptions, and geopolitical events. The company's performance reflects these pressures, particularly in its IV solutions business due to customer conservation practices and in its overall cost structure. Regulatory scrutiny, as evidenced by the FDA recalls and ongoing tax audits, remains a significant factor for medical device and pharmaceutical companies. The strategic divestiture of the Kidney Care business aligns with a broader industry trend of companies streamlining portfolios to focus on core strengths, while the associated dis-synergies highlight the complexities of such separations.

Comparison to Industry Standards

• The reported gross margin of 33.5% for Q3 2025 is a notable decline from 38.3% in the prior year, indicating pressure on profitability. This is below the average gross margins for many established medical device companies, which often range from 50% to 70%, suggesting the company faces significant cost of sales challenges or pricing pressures compared to peers like Medtronic or Abbott Laboratories.
• The net loss for the quarter, driven by special items and operational challenges, contrasts with the generally profitable performance seen across the broader medical technology sector, where companies like Stryker or Intuitive Surgical typically report positive net income.
• The operational sales growth of 2% is modest compared to some high-growth segments within the medical device industry, particularly those focused on innovative technologies or elective procedures that have seen a post-pandemic rebound. However, it is in line with or slightly below the growth rates of more mature, diversified healthcare product companies.
• The significant debt repayment of $3.81 billion following the Kidney Care divestiture is a positive step towards deleveraging, a common strategy among large healthcare companies seeking to optimize their capital structure and improve financial flexibility, similar to recent actions by GE HealthCare or Danaher in divesting non-core assets.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing involvement as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites, with an agreement in principle to resolve liability at a seventh site.
• 38 complaints currently filed and pending in the Circuit Court of Cook County, Illinois, alleging injuries from ethylene oxide exposure at the Round Lake, Illinois facility, with an agreement in principle to resolve these cases for an amount not material to Baxter.
• Cooperating fully with the DOJ in responding to a Civil Investigative Demand (CID) and a 2024 Subpoena issued to Hillrom related to compliance with the False Claims Act and Anti-Kickback Statute (allegations relate to conduct prior to Baxter's acquisition of Hillrom).
• Ongoing fact discovery in the Linet Americas, Inc. antitrust lawsuit against Hillrom, alleging anti-competitive conduct in markets for standard, ICU, and birthing beds.
• Reading Hospital's putative class action complaint against Hillrom, alleging similar antitrust violations, was dismissed with prejudice on September 12, 2025, but the plaintiff filed a Notice of Appeal on October 9, 2025.
• A class action complaint was filed on October 16, 2025, against Baxter and certain current/former officers/employees, alleging violations of the Securities Exchange Act of 1934 related to allegedly false and misleading statements and failure to disclose material facts concerning the Novum LVP.

Related Party Transactions

• Baxter and Vantive (formerly Kidney Care business, sold to Carlyle) entered into several agreements upon closing the sale, including a Manufacturing and Supply Agreement (Kidney Care MSA) for up to 10 years, and a Transition Services Agreement (Kidney Care TSA) for up to 30 months.
• Sales to Vantive under the Kidney Care MSA are recognized in net sales.
• Billings by Baxter under the Kidney Care TSA are recorded in other operating income, net.
• Baxter has agreed to indemnify Vantive for certain items, including pre-closing taxes ($57 million net indemnification liability as of Sep 30, 2025).
• Baxter recorded a contingent liability of $124 million (as of Sep 30, 2025) for payments to reimburse Vantive for qualifying capital expenditures over three years post-sale.
• Baxter retains approximately $230 million in legacy guarantees for the Kidney Care business, with Carlyle agreeing to indemnify Baxter for any future costs or payments under these arrangements.

Stakeholder Impact

• Shareholders experienced a net loss for the quarter and a reduction in quarterly dividends, reflecting decreased profitability and potential concerns about future returns.
• Customers of Novum LVP are impacted by the temporary distribution and installation hold and recalls, potentially requiring them to use alternative products like Spectrum IQ.
• Hospital customers in the U.S. IV Solutions business are continuing fluid conservation practices, leading to reduced demand for Baxter's products.
• Employees may be affected by ongoing business optimization programs and restructuring actions aimed at reducing cost structure following the Kidney Care sale.
• Regulatory bodies (FDA, IRS) are actively engaged with the company regarding product recalls, manufacturing compliance, and tax matters, indicating ongoing scrutiny.
• Creditors face a revised negative credit rating outlook and a review for downgrade from Moody's, which could impact borrowing costs and perception of creditworthiness, despite significant debt repayments.

Next Steps

• Continue developing and implementing additional corrections for the Novum LVP, some of which will require regulatory approval.
• Manage inventory and minimize disruption to patient care while the Novum LVP distribution/installation hold remains in effect.
• Pursue cost savings initiatives, including those to mitigate dis-synergies from the Kidney Care business sale, and potentially incur additional restructuring charges.
• Monitor regulatory guidance and interpretations regarding the OBBBA and Pillar Two tax legislation.
• Respond to inquiries and engage in ongoing discussions with the IRS regarding transfer pricing matters for tax years 2019 and 2020.
• Continue to closely monitor the performance of the Front Line Care reporting unit for potential future goodwill impairment.

Key Dates

Recommendation

The filing presents a mixed financial picture with significant headwinds. While the company successfully divested its Kidney Care business and used proceeds to reduce debt, the reported net loss for the quarter, substantial decline in gross margin, and significant special charges (tax reserves, product recalls) are concerning. Operational challenges, particularly the ongoing Novum LVP recall and reduced IV solution demand, are expected to persist. The negative credit rating outlook from Moody's adds to the uncertainty. However, the company is actively pursuing cost optimization and some segments show growth. Given the current operational challenges and financial pressures, but also strategic actions to streamline and deleverage, a 'hold' recommendation is appropriate. Investors should await further clarity on the resolution of product recalls, tax audits, and the effectiveness of cost-saving initiatives before making more aggressive investment decisions.

Keywords

Baxter International, BAX, 10-Q, Quarterly Report, Medical Devices, Healthcare, Financial Results, Novum LVP Recall, Kidney Care Sale, Debt Repayment, Tax Reserves, Gross Margin, EPS, Infusion Therapies, Advanced Surgery, Healthcare Systems & Technologies, Pharmaceuticals, Supply Chain, Regulatory Compliance, FDA, IRS Audit, Credit Rating, Business Optimization, Andrew Hider